The 'non-falciparum' malarias: the roles of epidemiology, parasite biology, clinical syndromes, complications and diagnostic rigour in guiding therapeutic strategies

Plasmodium vivax, P. ovale, P. malariae and P. falciparum routinely infect humans. The infections caused by these parasites are loosely referred to as vivax (or benign tertian), ovale, malariae (or quartan) and falciparum (or malignant tertian) malaria, respectively. Recently, P. knowlesi, a parasit...

Full description

Saved in:
Bibliographic Details
Published in:Annals of tropical medicine and parasitology 2010-06, Vol.104 (4), p.283-301
Main Authors: Maguire, J. D., Baird, J. K.
Format: Article
Language:English
Subjects:
Animals
Antimalarials - therapeutic use
Biological and medical sciences
General aspects
Human protozoal diseases
Humans
Infectious diseases
Macaca
Malaria
Malaria - drug therapy
Malaria - epidemiology
Malaria - parasitology
Medical sciences
Parasitic diseases
Plasmodium - physiology
Plasmodium falciparum
Plasmodium vivax
Protozoal diseases
Secondary Prevention
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Plasmodium vivax, P. ovale, P. malariae and P. falciparum routinely infect humans. The infections caused by these parasites are loosely referred to as vivax (or benign tertian), ovale, malariae (or quartan) and falciparum (or malignant tertian) malaria, respectively. Recently, P. knowlesi, a parasite of macaque monkeys in South-east Asia, has been identified as the cause of uncomplicated and severe human malaria in Malaysian Borneo. The prescription of appropriate therapies for reliably diagnosed malaria requires a grasp of the epidemiology of the 'non-falciparum' malarias, the biology of the parasites involved, the chemotherapeutic strategies that are available and the problems of emerging drug resistance and changing clinical syndromes. This review is intended to increase clinicians' understanding of how these factors relate to the selection of the antimalarial drugs to be given to a case of 'non-falciparum' malaria, with the aims of improving outcomes and preventing relapses and recrudescences.
ISSN:0003-4983
1364-8594
DOI:10.1179/136485910X12743554760027